2 weeks Ago
CONMED Corporation ( NYSE: CNMD ) Q3 2024 Earnings Conference Call October 30, 2024 4:30 PM ET Company Participants Curt Hartman – Chairman, President and Chief Executive Officer Pat Beyer – Chief Operating Officer Todd Garner – Executive Vice President and Chief Financial Officer Conference Call Participants Kristen Stewart – C.L. King Lily Delaney – JPMorgan Dino Weinstock – Wells Fargo Operator Good day and thank you for standing by.
Welcome to CONMED’s Third Quarter Fiscal 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the Speaker’s presentation, there will be a question-and-answer session.
[Operator Instructions] Please be advised that today’s conference is being recorded. Before the conference call begins, let me remind you that during this call management will be making comments and statements regarding its financial outlook, its plans and objectives. These statements represent the forward-looking statements that involve risks and uncertainties as those terms are defined under the federal securities laws.
Investors are cautioned that any such forward-looking statements are not guarantees of future events, performance or results. The company’s actual results may differ materially from its current expectations please refer to the risks and other uncertainties disclosed under the forward-looking information in today’s press release as well as the company’s SEC filings for more details on the risks and uncertainties that may cause actual results to differ materially. The company disclaims any obligation to update any forward-looking statements that may be discussed during this call, except as may be required by applicable law.
You will also hear management refer to non-GAAP or adjusted measurements during this discussion. While these figures are not a substitute for GAAP measurements, management uses these figures to aid in monitoring the company’s ongoing financial performance from quarter-to-quarter and year-to-year on a regular basis and for benchmarking against other medical technology companies..
